Rutgers Cancer Institute of New Jersey — Newark, New Jersey

Rutgers Cancer Institute of New Jersey is a clinical research site located in Newark, New Jersey, United States 08901.

Crixeo Health Trust Score: 56/100 (POOR). This profile has not yet been claimed by the site owner.

Rutgers Cancer Institute of New Jersey has participated in 2 clinical trials with 1 currently active.

Therapeutic areas: HER2 Positive Gastric Cancer, Metastatic HER2 Positive Gastroesophageal Junction Cancer, Head and Neck Cancer.

Sponsors: Triumvira Immunologics, Inc., ALX Oncology Inc..

Sponsor Feasibility Report

Trust Score: 56/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Rutgers Cancer Institute of New Jersey?

Rutgers Cancer Institute of New Jersey has a Crixeo Trust Score of 56/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Rutgers Cancer Institute of New Jersey conducted?

Rutgers Cancer Institute of New Jersey has 2 clinical trials on record, with 1 currently active. Their work covers HER2 Positive Gastric Cancer, Metastatic HER2 Positive Gastroesophageal Junction Cancer, Head and Neck Cancer.

Is Rutgers Cancer Institute of New Jersey accredited by Crixeo Health?

Rutgers Cancer Institute of New Jersey has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Rutgers Cancer Institute of New Jersey?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.